Inogen Inc. (NASDAQ:INGN)’s share price dropped 2.3% during trading on Friday . The stock traded as low as $50.15 and last traded at $50.16, with a volume of 115,958 shares changing hands. The stock had previously closed at $51.35.

INGN has been the subject of several analyst reports. Piper Jaffray Cos. initiated coverage on shares of Inogen in a research report on Thursday, March 24th. They set a “neutral” rating and a $46.00 price target for the company. Needham & Company LLC reissued a “strong-buy” rating and set a $58.00 price target (up previously from $47.00) on shares of Inogen in a research report on Tuesday, May 10th. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Stifel Nicolaus reissued a “buy” rating and set a $52.00 price target (up previously from $46.00) on shares of Inogen in a research report on Tuesday, May 10th. Finally, Leerink Swann reissued an “outperform” rating and set a $60.00 price target on shares of Inogen in a research report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $52.83.

The company has a market capitalization of $1.01 billion and a PE ratio of 86.04. The company has a 50 day moving average of $49.18 and a 200-day moving average of $42.46.

Inogen (NASDAQ:INGN) last released its earnings results on Monday, May 9th. The medical technology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by $0.01. The firm had revenue of $43 million for the quarter, compared to analysts’ expectations of $41.75 million. The business’s quarterly revenue was up 27.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 earnings per share. Equities analysts predict that Inogen Inc. will post $0.60 earnings per share for the current year.

In related news, CEO Raymond Huggenberger sold 20,747 shares of the business’s stock in a transaction on Thursday, June 16th. The shares were sold at an average price of $47.86, for a total value of $992,951.42. Following the sale, the chief executive officer now owns 27,555 shares in the company, valued at $1,318,782.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matt Scribner sold 4,102 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $43.82, for a total transaction of $179,749.64. Following the completion of the sale, the executive vice president now owns 6,435 shares in the company, valued at approximately $281,981.70. The disclosure for this sale can be found here.

A number of large investors have made changes to their positions in INGN. California State Teachers Retirement System boosted its stake in shares of Inogen by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,132 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 400 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Inogen by 18.1% in the fourth quarter. Sei Investments Co. now owns 31,851 shares of the medical technology company’s stock valued at $1,277,000 after buying an additional 4,880 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Inogen during the fourth quarter valued at $2,419,000. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Inogen by 29.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 93,441 shares of the medical technology company’s stock valued at $3,746,000 after buying an additional 21,141 shares in the last quarter. Finally, Thornburg Investment Management Inc. boosted its stake in shares of Inogen by 7.7% in the fourth quarter. Thornburg Investment Management Inc. now owns 230,995 shares of the medical technology company’s stock valued at $9,261,000 after buying an additional 16,500 shares in the last quarter.

Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.